ICBI Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
2ndary - Private
- Latest Deal Amount
-
$7.5M
- Investors
-
3
ICBI General Information
Description
Developer of a smart molecule technology designed to deliver therapeutic drugs across the blood-brain barrier and into the central nervous system. The company's technology penetrates any tissue in the body and brings smart molecules with lower bulk and less likelihood of side effects to areas of the body affected by other diseases, enabling medical professionals and doctors to treat Alzheimer's and Parkinson's disease.
Contact Information
Website
www.icbii.comCorporate Office
- 505 Coast Boulevard South
- Suite 405, La Jolla
- San Diego, CA 92037
- United States
Corporate Office
- 505 Coast Boulevard South
- Suite 405, La Jolla
- San Diego, CA 92037
- United States
ICBI Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 01-Oct-2021 | $7.5M | Completed | Pre-Clinical Trials | ||
| 3. Later Stage VC | 01-Dec-2018 | Completed | Pre-Clinical Trials | |||
| 2. Later Stage VC | 19-Apr-2013 | $895K | $895K | Completed | Pre-Clinical Trials | |
| 1. Grant | 01-Jan-2013 | Completed | Pre-Clinical Trials |
ICBI Comparisons
Industry
Financing
Details
ICBI Competitors (92)
One of ICBI’s 92 competitors is Casma Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Casma Therapeutics | Venture Capital-Backed | Cambridge, MA | ||||
| Angiochem | Formerly VC-backed | Westmount, Canada | ||||
| AB Science | Formerly Accelerator/Incubator backed | Paris, France | ||||
| Travecta Therapeutics | Formerly VC-backed | Singapore, Singapore | ||||
| Monte Rosa Therapeutics | Formerly VC-backed | Boston, MA |
ICBI Patents
ICBI Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2664625-A2 | Blood-brain barrier permeable peptide compositions | Active | 09-Jan-2012 | ||
| EP-2664625-A3 | Blood-brain barrier permeable peptide compositions | Active | 09-Jan-2012 | ||
| EP-2664625-B1 | Blood-brain barrier permeable peptide compositions | Active | 09-Jan-2012 | ||
| EP-2754670-A1 | Blood-brain barrier permeable peptide compositions | Active | 09-Jan-2012 | ||
| EP-2754670-B1 | Blood-brain barrier permeable peptide compositions | Active | 09-Jan-2012 | C07K16/18 |
ICBI Signals
ICBI Investors (3)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Baywater | Venture Capital | Minority | ||
| Solve Ventures | Corporate Venture Capital | Minority | ||
| Michael J. Fox Foundation | Limited Partner |
ICBI FAQs
-
When was ICBI founded?
ICBI was founded in 2008.
-
Where is ICBI headquartered?
ICBI is headquartered in San Diego, CA.
-
What is the size of ICBI?
ICBI has 11 total employees.
-
What industry is ICBI in?
ICBI’s primary industry is Drug Discovery.
-
Is ICBI a private or public company?
ICBI is a Private company.
-
What is ICBI’s current revenue?
The current revenue for ICBI is .
-
How much funding has ICBI raised over time?
ICBI has raised $895K.
-
Who are ICBI’s investors?
Baywater, Solve Ventures, and Michael J. Fox Foundation have invested in ICBI.
-
Who are ICBI’s competitors?
Casma Therapeutics, Angiochem, AB Science, Travecta Therapeutics, and Monte Rosa Therapeutics are some of the 92 competitors of ICBI.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process